CDK5 and Parkinson disease: AAV9-GFP-CIP alleviated not only motor symptoms but also non-motor symptoms in MPTP/p induced PD model mice, suggesting that inhibition of hyperactivity of Cdk5/p25 by CIP might be a new strategy for the treatment of neurodegenerative diseases including AD and PD.